Standout Papers

Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in Chi... 2015 2026 2018 2022 3.8k
  1. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study (2015)
    Yiyun Liu, Yang Wang et al. The Lancet Infectious Diseases
  2. The global epidemiology of carbapenemase-producing Enterobacteriaceae (2016)
    David van Duin, Yohei Doi Virulence
  3. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial (2020)
    Matteo Bassetti, Roger Echols et al. The Lancet Infectious Diseases
  4. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae (2017)
    David van Duin, Judith J. Lok et al. Clinical Infectious Diseases
  5. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) (2020)
    Mohamed Abd El-Gawad El-Sayed Ahmed, Lan-Lan Zhong et al. Emerging Microbes & Infections
  6. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections (2019)
    Yohei Doi Clinical Infectious Diseases
  7. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens (2012)
    Zubair Qureshi, David L. Paterson et al. Antimicrobial Agents and Chemotherapy
  8. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections (2016)
    Ryan K. Shields, Liang Chen et al. Antimicrobial Agents and Chemotherapy
  9. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia (2017)
    Ryan K. Shields, M. Hong Nguyen et al. Antimicrobial Agents and Chemotherapy
  10. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19 (2024)
    Hiroshi Yotsuyanagi, Norio Ohmagari et al. JAMA Network Open

Immediate Impact

1 by Nobel laureates 22 from Science/Nature 118 standout
Sub-graph 1 of 19

Citing Papers

Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches
2025 Standout
66 intermediate papers

Works of Yohei Doi being referenced

Antibacterial Resistance Leadership Group 2.0: Back to Business
2021
Elastase Activity From Pseudomonas aeruginosa Respiratory Isolates and ICU Mortality
2021
and 66 more

Author Peers

Author Last Decade Papers Cites
Yohei Doi 16949 5820 4338 5968 367 21.5k
Karen Bush 16944 5275 4165 7145 216 22.1k
Gian María Rossolini 16081 6323 4182 4163 555 22.8k
Christian G. Giske 14639 5468 5335 4012 227 21.6k
Neil Woodford 17013 7898 4037 4701 349 23.4k
Timothy R. Walsh 19463 7983 3243 4424 307 25.6k
George A. Jacoby 18170 6515 3809 5820 152 22.4k
Thierry Naas 15486 7427 2766 4010 346 20.0k
David C. Hooper 12498 3409 4683 6846 270 23.4k
David M. Livermore 23138 8098 6357 8586 402 31.0k
Johann Pitout 13979 7636 4064 2508 198 16.6k

All Works

Loading papers...

Rankless by CCL
2026